<DOC>
	<DOCNO>NCT01256385</DOCNO>
	<brief_summary>This phase II trial study well give temsirolimus together cetuximab work compare temsirolimus alone treat patient recurrent and/or metastatic head neck cancer respond previous therapy . Temsirolimus may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . It yet know whether give temsirolimus together cetuximab effective give temsirolimus alone .</brief_summary>
	<brief_title>Temsirolimus With Without Cetuximab Patients With Recurrent and/or Metastatic Head Neck Cancer Who Did Not Respond Previous Therapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Primary endpoint progression free survival ( PFS ) cetuximab/temsirolimus combination cohort ( Arm A ) compare temsirolimus alone ( Arm B ) . SECONDARY OBJECTIVES : I. Progression-free survival ( PFS ) cetuximab/temsirolimus combination group ( Arm A ) temsirolimus control group ( Arm B ) compare historic control cohort . II . Subgroup analysis myofibroblast ( + ) cohort ( PFS ) . III . Overall survival ( OS ) . IV . Toxicities . V. Response ( Response Evaluation Criteria Solid Tumors [ RECIST ] ) /absolute tumor shrinkage ( waterfall plot analysis ) . VI . Activity combination therapy ( temsirolimus/cetuximab ) failure ( progressive disease [ PD ] ) temsirolimus monotherapy . OUTLINE : Patients randomize 1 2 treatment arm . ARM A : Patients receive temsirolimus intravenously ( IV ) 30-60 minute cetuximab IV 1-2 hour weekly . Courses repeat every 4 week absence disease progression unacceptable toxicity . ARM B : Patients receive temsirolimus Arm A . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients progressive disease may cross Arm A . After completion study therapy , patient follow minimum 8 week year 5 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Verrucous</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically/cytologically confirm diagnosis squamous cell carcinoma head neck origin amenable curative intent therapy ; information prior exposure cetuximab ( duration , single agent/combined chemotherapy/combined radiation , best response , interval prior study entry ) collect Progressive disease RECIST criterion ( unequivocal clinical progression ) cetuximab base therapy line therapy recurrent/metastatic disease ; prior use cetuximab recurrent/metastatic disease define palliative intent use either alone combination chemotherapy minimum 2 week uninterrupted treatment cetuximab ; treatment cetuximab radiotherapy chemoradiotherapy sufficient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 Presence measurable lesion RECIST : patient must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; = 20 mm conventional technique &gt; = 10 mm spiral compute tomography ( CT ) scan Knowledge anatomic site original tumor ( oropharynx versus nonoropharynx ) alternatively human papilloma virus ( HPV ) status ; trial stratify patient oropharynx versus nonoropharynx origin ; HPV ( + ) tumor count oropharynx cohort , HPV ( ) tumor nonoropharynx cohort ; later point patient undergo HPV test part trial ; widely use form HPV test acceptable ( include limit HPV situ hybridization [ ISH ] , p16 test [ immunohistochemistry ( IHC ) ] , HPV16 testing , polymerase chain reaction [ PCR ] , hybrid capture , etc ) Availability formalinfixed , paraffinembedded ( FFPE ) tissue blood FFPE : &gt; =14 slide contain tumor , 18 recommend 710 slide 5 um thick , AND 710 slide 10 um thick , cut clean blade ( use new blade possible clean vigorously avoid RNA/DNA , RNase contamination ) Blood : two 10 cc ethylenediaminetetraacetic acid ( EDTA ) purple top tube ( blood ) ; two 2 ml cryovials ( serum ) Patients human immunodeficiency virus ( HIV ) , require highly active antiretroviral treatment ( HAART ) therapy eligible Life expectancy great 8 week Leukocytes &gt; = 2,000/mcL Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Total bilirubin within normal institutional limit ( unless prove Gilbert 's disease , principal investigator [ PI ] approval patient may include ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 X institutional upper limit normal Creatinine within 1.5 X normal institutional limit Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation Ability understand willingness sign write informed consent document Fasting glucose = &lt; 120 mg/dl glycosylated hemoglobin ( HbA1c ) = &lt; 7.5 % Patients chemotherapy radiotherapy within 2 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 2 week earlier Patients may receive investigational agent Patients know , active brain metastasis exclude clinical trial ; patient treat brain metastasis stable &gt; = 12 week eligible History allergic reaction attribute compound similar chemical biologic composition temsirolimus cetuximab Concurrent lifethreatening disease : patient diseases reasonable certainty limit life expectancy 12 month less eligible ; assessment concurrent illness principal investigator Use strong inhibitors/inducers CYP3A4 permit Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study Breastfeeding discontinue mother treat temsirolimus HIVpositive patient normal immune function ( CD4 count &gt; 200 ) eligible drug interaction temsirolimus cetuximab ; patient impair immune function ineligible due risk additional immunosuppression temsirolimus therapy Concurrent administration temsirolimus vaccination avoid 14day window administration vaccine advise ; emergent situation policy may revisit PI deem important patient 's health Poorly control hyperglycemia ( HbA1C &gt; 7.5 % ) hyperlipidemia exclusion criterion ; hyperglycemia hyperlipidemia need appropriately manage control Concurrent use warfarin allow , require close monitor prothrombin time ( PT ) /international normalize ratio ( INR ) Patients clinically significant pneumonitis/pulmonary infiltrates unless know treatable cause condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>